In this review, we will focus on the standard-of-care treatments for HER2+ breast cancer patients, the current HER2-targeted therapies being tested in the clinical setting or those that have shown promising results in preclinical models, and potential combinations with other treatments, such as immunotherapies, to achieve cancer remission in HER2+ and HER2-low breast cancer subtypes. Here, ERBB2 is linked to breast cancer.